


L'articulation droit de la concurrence - droit de propriété intellectuelle


Séminaire Nasse
Paris, 9 Novembre 2017

CRA Charles River
Associates

Laurent Flochel - Vice President CRA




Patent owner has an incentive to protect his monopoly profit



Monopoly profit



Duopoly profit



Monopoly profit after settlement

Probabilistic patents

Lemley, Shapiro

- Very few patents are litigated and even less go to trial
- Very few patents have a commercial significance

Optimal policy [optimal allocation of (scarce) resources]:

- Improving the system of granting patents or
- Controlling *ex post* some agreements with commercial interest

➤ **Probabilistic patents** (right to try to exclude and not right to exclude)

Two concerns about patent settlements

1. Concerns about settlements that prevent **weak patents** from being “weeded out” by the courts
 - The extreme case of *sham patents*
2. Concerns about settlements in which consumer welfare is less than the expected consumer welfare if the parties had litigated
 - Incentive to delay entry until patent expiration

Preliminary remarks – the « IP bargain »

➤ **Patent** :


- Reward for an innovation and R&D investment
 - rent given to the innovator (right to exclude, license, settle if more profitable)
- Ex post dead weight loss for consumers

➤ **IP bargain**: trade-off between these two opposite effects (dynamic efficiencies)

The game

Bargaining

Trial



Injunction ?


p_i : belief by i that he will win the litigation

Settlement:

- Value transfer
- Other (compensation on other markets, early entry, ...)

Is there a room for a deal?

- Each party estimates his willingness to pay / willingness to accept (e.g. innovator (A) pays, generic (B) receives)



Willingness to pay (to accept) depends on :

- belief on the probability of winning the trial
- litigation costs

The asymmetric risk

Each party does not face the same risk in going to the trial

➤ **Innovator:**

- Loses its profit on some markets
- Side effects on other markets if reference pricing
- Difficulty to be entirely compensated if wins the trial (limited responsibility, potentially huge damages – eg “at risk” entry)
- Enhanced if injunction is difficult to obtain
- Litigation costs

➤ **Generic:**

- Litigation costs

Consequences:

- A patent holder can have a rational incentive to pay significantly more than anticipated litigation expenses to settle patent litigation even when it believes there is a high probability that it will win at trial
- A settlement payment that significantly exceeds litigation expenses cannot be treated as evidence of a sham patent

Value transfer settlements

➤ **Value transfer** facilitates the settlement

- Amount is certain (any other compensation would incur a risk)
- No reason that the value transfer would be limited to the amount of the (saved) litigation costs

=> Value transfer settlements should not be seen as negative *per se*

The articulation between antitrust and IPR

- Should private incentives to settle be aligned with some social welfare objectives?
 - No more than for a patent owner to set his price in order to maximize social welfare
- Should Antitrust compensate for some potential failures of the IPR system?
 - Why not addressing these potential failures with IP law/ rules?
 - Optimal allocation of resources between improving granting system and selective ex post control (probabilistic patents)
- Limitating the ability of patent owners to settle decreases their potential profit and therefore their reward for R&D investments and innovation
 - Negative effect on innovation